Lead Product(s) : Fexofenadine Hydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2010
Lead Product(s) : Fexofenadine Hydrochloride
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Isosorbide
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Isosorbide
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 07, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Will Present at the Bioprocessing Summit Europe Conference on March 22, 2022 in Barcelona
Details : SENS-401 is a first-in-class drug candidate to treat Sudden Sensorineural Hearing Loss, aiming at treating or protecting against inner ear lesions that lead to nerve degeneration and sensory hair cell loss.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 demonstrated a statistically significant effect with the high dose on pure tone audiometry (≥ 10 decibels improvement vs placebo) in Phase 2 AUDIBLE-S trial in SSNHL at Day 84 in per protocol idiopathic population (81 patients) treated with co...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Association for Research in Otolaryngology
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 (R-azasetron besylate), oral small molecule lead asset currently being investigated in sudden sensorineural hearing loss and cisplatin-induced ototoxicity aims to protect and preserve inner ear tissue from damage.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Association for Research in Otolaryngology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rimegepant Sulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biohaven Enrolls First Patient in Phase 2/3 Sinusitis Trial of Nurtec® ODT
Details : Nurtec ODT, oral calcitonin-gene related peptide receptor antagonist currently approved for the acute and preventive treatment of migraine. Prior research has implicated CGRP in pathophysiology of disease and suggested therapeutic benefits of CGRP antago...
Product Name : Nurtec ODT
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 22, 2022
Lead Product(s) : Rimegepant Sulfate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SENS-401 (R-azasetron besylate) is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2022
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Cochlear Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022
Details : SENS-401 (Arazasetron), is a drug candidate that aims to protect and preserve inner ear tissue from damage that can cause progressive or sequelar hearing impairment.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 27, 2021
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Cochlear Limited
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sensorion Presents New Preclinical Data on SENS-401 at ARO 2021
Details : The poster presented shows SENS-401 ability to yield significant treatment benefits in rats with severe hearing loss when initiated with a delay up to 7 days after the initial acoustic trauma.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2021
Lead Product(s) : R-Azasetron Besylate
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable